| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -69,234 | -86,981 | -82,175 | -142,195 |
| Stock-based compensation expense | 16,007 | 14,453 | 15,802 | 29,649 |
| Lease impairment charge | NaN | NaN | 3,855 | 0 |
| Impairment of long-lived assets | NaN | 3,856 | NaN | NaN |
| Depreciation and amortization | 2,022 | 2,032 | 2,149 | 4,132 |
| Premiums and discounts on available-for-sale marketable securities | -2,730 | -2,045 | -2,188 | -4,646 |
| Prepaid expenses and other current assets | 3,565 | 322 | -266 | 2,305 |
| Accounts receivable | NaN | 0 | -40,000 | 40,000 |
| Contract asset | 0 | 0 | 0 | -947 |
| Other non-current assets | NaN | NaN | -2,153 | -2,725 |
| Accounts payable | 8,824 | -1,491 | -267 | -216 |
| Accrued expenses and other current liabilities | -7,209 | 13,662 | 664 | -6,939 |
| Deferred revenue | -34,365 | -2,871 | -2,764 | 26,424 |
| Operating lease right-of-use assets | -615 | -596 | -708 | -1,362 |
| Operating lease liabilities | -1,358 | -1,329 | -1,297 | -2,416 |
| Other non-current assets | NaN | 7,164 | NaN | NaN |
| Other non-current liabilities | NaN | 18 | NaN | NaN |
| Other assets and liabilities | -1,969 | NaN | -290 | 106 |
| Net cash used in operating activities | -88,840 | -66,747 | -27,110 | -139,034 |
| Purchase of property and equipment, net | 434 | 106 | 181 | 1,162 |
| Purchase of marketable securities | NaN | 1,007,628 | NaN | NaN |
| Purchases of investments | -233,199 | NaN | 367,558 | 141,907 |
| Maturities of marketable securities | NaN | 488,016 | NaN | NaN |
| Maturities of investments | -250,285 | NaN | 132,440 | 251,705 |
| Proceeds from employee stock purchase plan | NaN | 573 | 0 | 1,112 |
| Net cash provided by (used in) investing activities | -142,840 | -394,398 | -235,299 | 108,636 |
| Issuance of common stock and accompanying pre-funded warrants from january 2024 public offering, net of issuance costs of 14.9 million | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock through at-the market sales agreement, net of issuance costs of 1.2 million | NaN | 0 | 0 | 0 |
| Issuance of common stock and accompanying pre-funded warrants from august 2024 public offering, net of issuance costs of 12.2 million | NaN | 0 | 237,294 | -237,294 |
| Issuance of common stock and accompanying pre-funded warrants from june 2025 public offering, net of issuance costs of 15.7 million | NaN | 0 | -272,671 | NaN |
| Issuance of common stock from december 2025 public offering, net of issuance costs of 36.2 million | NaN | -656,230 | NaN | NaN |
| Proceeds from stock option exercises | 19,194 | 48,832 | 4,552 | 8,237 |
| Payments on finance leases | 425 | 416 | 419 | 659 |
| Net cash provided by financing activities | 18,769 | 705,219 | 39,510 | 245,984 |
| Net decrease in cash, cash equivalents and restricted cash | -212,911 | 244,074 | -222,899 | 215,586 |
| Cash, cash equivalents and restricted cash at beginning of period | 362,811 | 118,737 | 126,050 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 149,900 | 362,811 | 118,737 | NaN |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)